Company news
Inovio Pharmaceuticals, Inc. news in 2023
Inovio Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
November 8, 2023
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
October 25, 2023
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
October 9, 2023
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
September 6, 2023
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
August 8, 2023
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
July 25, 2023
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
June 22, 2023
INOVIO to Present at the 2023 Jefferies Healthcare Conference
May 24, 2023
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
May 22, 2023
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
May 9, 2023
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
May 7, 2023
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 4, 2023
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
April 27, 2023
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
April 26, 2023
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
April 11, 2023
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
February 28, 2023
INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
February 15, 2023
INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023
February 14, 2023
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
February 1, 2023
INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
January 30, 2023
Calls in 2023
- Inovio Pharmaceuticals (NASDAQ:INO) Q3 2023 Earnings Call
Nov 9, 2023
Transcript - Inovio Pharmaceuticals (NASDAQ:INO) Q2 2023 Earnings Call
Aug 9, 2023
Transcript - Inovio Pharmaceuticals (NASDAQ:INO) Q1 2023 Earnings Call
May 10, 2023
Transcript - Inovio Pharmaceuticals (NASDAQ:INO) Q4 2022 Earnings Call
Mar 1, 2023
Transcript
Decks in 2023
- Q3 2023 Earnings Presentation
Earnings · 28 slides · Nov 9, 2023
- H.C. Wainwright 25th Annual Global Investment Conference (September 2023)
Conference · 22 slides · Sep 12, 2023